Autopsy report · NCT02086487

Efficacy and Safety Assessment of NIlotinib in CML Patients With Suboptimal Response on Imatinib Therapy

“Because of many unseen obstacles resulted in poor accrual, study is terminated.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 11 months after it had already started.
• Ran for about 3 years 5 months before it stopped.
• 98 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 4

Sponsor

King Abdullah International Medical Research Center

Sponsor type

University, hospital or other

Conditions

Myeloid Leukemia, Chronic

Interventions

Nilotinib 300 mg.

Participants

98

Sites

2

Countries

Saudi Arabia

Trials that died the same way

• Pembrolizumab + Idelalisib for Lung Cancer Study
  “The study was terminated due to poor accrual.” (84% match in meaning)
• Pilot Study of the Treatment of Vascular Endothelial Growth Factor(VEGF)Signaling Pathway Inhibitor-Induced Hypertension
  “Study has been terminated due to poor accrual.” (83% match in meaning)
• Bortezomib and Carboplatin in Treating Patients With Metastatic Pancreatic Cancer
  “Study was terminated due to poor accrual” (83% match in meaning)
• Dehydroepiandrosterone (DHEA) and Letrozole in Treating Patients With Metastatic Breast Cancer
  “Study was terminated due to lack of accrual” (82% match in meaning)
• Obstruction of Malignancy: Percutaneous Renal vs Endoscopic Stent
  “Study stopped due to lack of accrual” (82% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.